CLDI Calidi Biotherapeutics, Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 1855485 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY19.9%
TTM EPS YoY192.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-373.6%
ROA-163.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets70.5%
Debt / equity0.41x
Current ratio1.27x
Interest coverage-252.18x
Cash quality & payout
Operating cash flow / net income0.99x
Accruals ratio-1.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | — | — | — | $45,000 |
| R&D expense | $9.74M | $8.88M | $13.01M | $7.26M |
| SG&A expense | $10.50M | $12.90M | $15.98M | $15.90M |
| Operating income | -$20.24M | -$21.78M | -$28.99M | -$23.13M |
| Interest expense | $100,000 | $700,000 | $1.10M | $200,000 |
| Pretax income | -$20.05M | -$22.20M | -$29.20M | -$25.42M |
| Income tax | $15,000 | $14,000 | $16,000 | $11,000 |
| Net income | -$19.91M | -$22.14M | -$29.22M | -$25.43M |
| EBITDA | -$18.59M | -$20.24M | -$28.60M | -$22.87M |
| EPS (basic) | -5.95 | -35.70 | -17.33 | 2.99 |
| EPS (diluted) | -5.95 | -35.70 | -17.33 | 2.99 |
| Weighted avg. shares (diluted) | 4,302 | 667 | 1.69M | 8.51M |
| Balance sheet | ||||
| Cash & equivalents | $5.82M | $9.81M | $2.17M | $590,000 |
| Receivables | — | — | — | $870 |
| Current assets | $6.26M | $10.23M | $4.30M | $786,000 |
| PP&E, net | $781,000 | $869,000 | $1.27M | $1.27M |
| Total assets | $8.86M | $14.18M | $10.02M | $2.60M |
| Current liabilities | $3.94M | $9.50M | $10.23M | $42.99M |
| Short-term debt | $90,000 | $3.22M | $807,000 | $5.42M |
| Long-term debt | $600,000 | $600,000 | $2.06M | — |
| Total debt | $690,000 | $3.82M | $2.87M | — |
| Total liabilities | $5.10M | $12.21M | $18.25M | $43.44M |
| Shareholders' equity | $3.76M | $1.53M | -$8.23M | -$50.44M |
| Net debt | -$5.13M | -$5.99M | $700,000 | — |
| Shares outstanding | 451,076 | 1.73M | 3.55M | 8.58M |
| Cash flow statement | ||||
| Operating cash flow | -$21.29M | -$19.69M | -$26.98M | -$13.21M |
| Investing cash flow | -$170,000 | -$16,000 | -$478,000 | -$494,000 |
| Financing cash flow | $17.46M | $27.36M | $29.04M | $12.09M |
| Depreciation & amortization | $1.65M | $1.53M | $392,000 | $260,000 |
| Stock-based compensation | $2.11M | $2.96M | $4.81M | $4.52M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.